# Weight-loss drug arms race heats up — Lilly's new pill cuts 21% while Novo touts Ozempic heart safety — long both LLY and NVO

_AI-generated trading idea · BULLISH · LLY, NVO_

> Canonical page: https://commonquant.ai/research/for-you/weight-loss-drug-arms-race-heats-up-lilly-s-new-pill-cuts-21--d955321f-d0f4-5cde-bd35-ba98c7345807

The weight-loss drug market isn't a one-trick story — Lilly and Novo are investing in a next wave of amylin drugs to follow their GLP-1 successes. That signals management confidence that demand will keep growing well beyond current products. Both stocks are the clearest beneficiaries, and news of pipeline expansion typically supports the shares even when the broader market wobbles on rates.

## Idea

The weight-loss drug market isn't a one-trick story — Lilly and Novo are investing in a next wave of amylin drugs to follow their GLP-1 successes. That signals management confidence that demand will keep growing well beyond current products. Both stocks are the clearest beneficiaries, and news of pipeline expansion typically supports the shares even when the broader market wobbles on rates.

## Advanced Analysis

### Verdict: a strong amylin thesis, but nothing to buy yet — wait for the reclaim

The idea's core claim — that Lilly and Novo are funding an amylin successor wave out of genuine confidence in durable obesity demand — gets real support from the fundamentals: Lilly's Q2 2026 revenue hit $23.0B, up 16.0% quarter over quarter, with operating cash flow more than doubling to $10.7B, and Lilly has grown its dividend about 15.3% a year. The strongest point for the trade is that cash engine at Lilly, which makes the pipeline spend look funded by conviction rather than hope. The strongest point against is Novo's deceleration: fiscal 2025 revenue growth of just 6.4%, free cash flow down 20.1% to DKK 59.0B, and return on equity down 17.6 points — meaning the weaker, more volatile name (annualized volatility of 49.5% versus Lilly's 38.0%) is getting nearly half the risk budget. The provisional ownership filing for the period ending September 30, 2026 also shows Lilly insiders as net open-market sellers of roughly $2.9M — a dated, provisional read, but directionally not confidence-building. Practically, there is nothing to buy yet: both stocks sit below their 50-day EMAs (LLY at $1,142.85 versus $1,162.51; NVO at $37.32 versus $43.32) with RSI far below the 45 trigger, and the entry rules never fired across 1,234 daily bars. The verdict flips to actionable if a daily close reclaims the 50-day EMA with RSI crossing 45 — or to outright avoidance if Lilly's next earnings confirms the margin compression and leverage jump we saw in Q2.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 70/100 |
| Trade readiness | 22/100 |
| Risk quality | 45/100 |
| Trigger proximity | 15/100 |
| Fundamentals trend | 52/100 |
| Score | 41/100 |
| Composite Score | 41/100 |
| Evidence Tier | rules\_not\_triggered |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | rules\_not\_triggered |

### Trade now: the reclaim hasn't happened yet — here is the exact setup

\*\*Nothing to buy today.\*\* This is a pullback-and-reclaim setup: the strategy wants a daily close back above the 50-day moving average, with the 14-day RSI crossing above 45 on the same turn and trend strength (ADX) above 20. Neither symbol is there. On LLY (last close $1,142.85), price sits $19.66 below the 50-day EMA of $1,162.51, RSI reads 36.7 against the 45 threshold, and ADX at 17.0 is under the 20 floor. On NVO (last close $37.32), price is $6.00 below its EMA of $43.32, RSI is deeply washed out at 19.7 versus 45, but ADX at 33.5 already passes. NVO is the closer of the two on trend strength and the further one on momentum.

\*\*What waiting means concretely:\*\* hold off until a daily bar closes back above the 50-day EMA (LLY above $1,162.51, NVO above $43.32) with RSI crossing above 45 and ADX above 20 at that moment. On LLY, a reclaim near the EMA with the current ADX gap still open means momentum and trend strength likely need several sessions to firm up — the RSI gap alone is 8.3 points. On NVO, the RSI gap is a steep 25.3 points, so a reclaim there would likely follow a sharp multi-day bounce rather than a one-day pop.

\*\*Risk framing once triggered:\*\* the rules risk 2.33% per position and take profit at 4.66%, roughly a 2-to-1 reward-to-risk, with positions capped at 25% of the book each. Level-based exits also apply: on LLY, resistance near $1,149.46 is the first upside marker and the second support zone near $1,079.22 guards the downside; on NVO, resistance near $37.44 is immediate overhead while a support level near $42.52 sits above the current price — a quirk of a heavily drawn-down chart (NVO is down about 41.7% from its range high and carries a historical max drawdown of 70.6% over the two-year lookback, so position sizing matters more here than on LLY).

One note on evidence: because no entry has opened on these rules across the evaluated history, there is no realized trade record to lean on — the plan rests on the live trigger levels, not past fills. The author has asked for an expanded but bounded search to test whether the thresholds are simply too strict; no robust alternative parameter setup has been established, so the levels above remain the live ones.

#### LLY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | LLY |
| Timeframe | 1d |

#### NVO price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | NVO |
| Timeframe | 1d |

### Lilly's Numbers Back the Amylin Pipeline Story

The idea argues that Lilly and Novo are investing in a next wave of amylin obesity drugs because management sees durable demand beyond the current GLP-1 franchise — and the most recent fundamentals at least don't contradict that read. Lilly's Q2 2026 (period ended June 30, 2026) revenue came in at $23.0B, up 16.0% from the prior quarter's $19.8B, and gross margin expanded 3.8 points to 85.8%. For fiscal 2025 as a whole, Lilly grew revenue 42.5% year over year, a growth rate that puts it around the 77th percentile of 914 Health Care peers. If demand were genuinely stalling, you would not expect that combination of scale and price/mix strength. The cash engine behind the pipeline spend also looks real. Lilly's operating cash flow more than doubled quarter over quarter in Q2 2026, from $5.3B to $10.7B (+100.5%), while net income of $7.1B implies a still-elite 30.9% net margin. Lilly pays a growing dividend on top of this — $6.00 per share in 2025, up from $3.40 in 2021, roughly 15.3% annual growth — which is hard to do if management doubted future cash generation. Novo's case rests more on quality than momentum. Its fiscal 2025 revenue of DKK 309.1B grew 6.4%, and the company still sits at the 96th percentile of Health Care peers on operating margin (41.3%), the 89th percentile on return on equity (52.8%), and the 99.9th percentile on free cash flow (DKK 59.0B). A 16.8% share of revenue reinvested into R&D — DKK 52.0B in 2025 — is consistent with the thesis's core claim: both companies are funding a successor wave of drugs, not coasting on the current one. On evidence tier: this is a watch-list setup, not an active signal. The entry rules were evaluated against real daily bars but never opened a trade — zero entries across 1,234 daily bars in the 60-month window, and zero again in the 24- and 12-month windows. That is a statement about entry conditions not having occurred, not a flaw in…

#### LLY Free cash flow

Free cash flow trend from CommonQuant fundamentals/XBRL data; +1386.5% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2019-03-31 | $107600000 |
| 2019-06-30 | $811200000 |
| 2019-09-30 | $1246700000 |
| 2020-03-31 | $124100000 |
| 2020-06-30 | $2213600000 |
| 2020-09-30 | $1413500000 |
| 2021-03-31 | $1397100000 |
| 2021-06-30 | $1394200000 |
| 2021-09-30 | $1294500000 |
| 2022-03-31 | $2157600000 |
| 2022-06-30 | $812300000 |
| 2022-09-30 | $1599500000 |
| Latest Value | $1599500000 |
| Change Pct | $1386.5241635687732 |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; +204.4% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \-0.3075084969648396% |
| 2009-06-30 | \0.13533878504672897% |
| 2009-09-30 | \0.09508329126703684% |
| 2009-12-31 | \0.45445287812457347% |
| 2010-03-31 | \0.1192949924968697% |
| 2010-06-30 | \0.13178900471896282% |
| 2010-09-30 | \0.10502599653379548% |
| 2010-12-31 | \0.4081624437412945% |
| 2011-03-31 | \0.07577758321252745% |
| 2011-06-30 | \0.08386215591510822% |
| 2011-09-30 | \0.0821030821030821% |
| 2011-12-31 | \0.3210601327750578% |
| Latest Value | \0.3210601327750578% |
| Change Pct | \204.40691426219928% |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY sector percentile check

Ranks LLY against 597 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Gross margin | \78.05695142378559th percentile |
| Revenue growth (YoY) | \76.91466083150985th percentile |
| Ticker | LLY |
| Sector | Health Care |
| Peer Count | 597 |

### Scores

- **Conviction score breakdown:** 41
- **Thesis support:** 70
- **Trade readiness:** 22
- **Risk quality:** 45
- **Trigger proximity:** 15
- **Fundamentals trend:** 52

### Watch items

- **LLY — Close vs 50-day EMA (reclaim)**
- **LLY — RSI (14)**
- **LLY — ADX (14)**
- **NVO — Close vs 50-day EMA (reclaim)**
- **NVO — RSI (14)**
- **LLY — Insider net open-market activity**
- **LLY — Net margin**
- **NVO — Free cash flow (annual)**
- **LLY — Next ex-dividend event**

## Key details

- Symbols: LLY, NVO
- Timeframes: 1d
- Tags: \#canonical-demand, \#cluster-version:1, \#direction:bullish, \#entity-kind:instrument, \#entity:LLY, \#entity:NVO, \#horizon:unspecified, \#intent:research, \#symbol:LLY, \#symbol:NVO

## Community

- Upvotes: 0
- Views: 0
- Copies: 0
- Cosigns: 0

## News sources

- [Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s](https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html) — CNBC

## Related

- [LLY trade ideas](https://commonquant.ai/markets/lly)
- [NVO trade ideas](https://commonquant.ai/markets/nvo)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.